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Abstract
Background: We describe the pioneering experience of a Spanish family pursuing the goal of understanding their
own personal genetic data to the fullest possible extent using Direct to Consumer (DTC) tests. With full informed
consent from the Corpas family, all genotype, exome and metagenome data from members of this family, are
publicly available under a public domain Creative Commons 0 (CC0) license waiver. All scientists or companies
analysing these data (“the Corpasome”) were invited to return results to the family.
Methods: We released 5 genotypes, 4 exomes, 1 metagenome from the Corpas family via a blog and figshare under a
public domain license, inviting scientists to join the crowdsourcing efforts to analyse the genomes in return for coauthorship
or acknowldgement in derived papers. Resulting analysis data were compiled via social media and direct email.
Results: Here we present the results of our investigations, combining the crowdsourced contributions and our own
efforts. Four companies offering annotations for genomic variants were applied to four family exomes: BIOBASE,
Ingenuity, Diploid, and GeneTalk. Starting from a common VCF file and after selecting for significant results from
company reports, we find no overlap among described annotations. We additionally report on a gut microbiome
analysis of a member of the Corpas family.
Conclusions: This study presents an analysis of a diverse set of tools and methods offered by four DTC companies. The
striking discordance of the results mirrors previous findings with respect to DTC analysis of SNP chip data, and highlights
the difficulties of using DTC data for preventive medical care. To our knowledge, the data and analysis results from our
crowdsourced study represent the most comprehensive exome and analysis for a family quartet using solely DTC data
generation to date.
Keywords: Crowdsourcing, Personal genomes, Participatory medicine, SNPs, Exome analysis, Microbiome, Family
genomes, Direct-to-consumer, Genetic testing, Genomics
Background
Direct-to-consumer (DTC) genetic testing has made it
possible for the general public to access personal genomics
information. A new sector has thus arisen in the biotechno-
logical industry capitalising on selling genomic tests directly
to the public, circumventing the need for consulting with a
clinician before taking a test. This has encouraged the
growth of P4 medicine (personalised, predictive, preventive
and participatory) [1–3] whereby patients can take control
of their own health and may be empowered to understand
potential health problems even before symptoms arise. The
Personal Genomes Project [4] also supports participation of
healthy individuals in genomics research by providing a
robust framework for sharing their data publicly with a
unique consent process. The rapid development of the field,
initially fuelled by companies such as 23andMe, deCODE
Genetics, and Navigenics, has enabled sharing of data and
development of methods for personal genomics analysis.
However, this has come at the price of ever increasing de-
mands on the breadth of knowledge and skills needed to in-
terpret genetic risks and the consequent burden on DTC
providers to keep up to date with scientific research. The
* Correspondence: manuel.corpas@tgac.ac.uk
†Equal contributors
1The Genome Analysis Centre, Norwich Research Park, Norwich, UK
Full list of author information is available at the end of the article
© 2015 Corpas et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Corpas et al. BMC Genomics  (2015) 16:910 
DOI 10.1186/s12864-015-1973-7
value of DTC predictions has recently been questioned by
the FDA, which has prohibited 23andMe from providing
clinically related inferences based on their customers’ geno-
type. DTC providers cannot offer all available methods and
scientific insights for any given set of genetic markers. This
can be particularly frustrating for users who may want to
explore further the raw data from which DTC predictions
are made or simply apply third party tools to the analysis of
their personal genomes themselves.
The power of family-based genomic analysis has been
established [5–8]. DTC companies currently offer very
limited support for genetic analyses involving more than
one individual, e.g., whole families [5, 9]. Privacy consid-
erations present additional challenges in family analyses,
since different individuals of a family may have different
comfort levels about sharing some or all of their per-
sonal genetic risks and data. In addition, this type of
information might have consequences for offspring and
children. Since members of a same family share much
of their genetic sequence (and hence information),
decisions made by one individual may affect the whole
family. Hence, family-based personal genomics analyses
may necessitate the re-evaluation of pre-established
notions of identity and privacy, and of data ownership.
Here we present the personal genomics analysis of a set
of exomes from a family (the Corpas family), and a micro-
biome analysis of an individual of this family. We build
from our crowdsourcing on the previously published ana-
lysis of five samples of the Corpas family using 23andMe
SNP chips [5]. We use DTC genetic testing with the goal
of exploring the process of participatory medicine per-
formed at the family level with current technology. One of
the family members is a scientist – the bioinformatician
leading this study (Manuel Corpas). After discussing priv-
acy issues, the family made a group decision to make their
personal genomics data publicly accessible and shareable.
The family made their genome data available under a
Creative Commons 0 (CC0) license waiver, with the under-
lying assumption that, by making their genomic data freely
available, the chances of receiving analysis results from
scientists and companies would be increased. Publicly
sharing personal genomes has been reported as one of
the driving factors for participants in open data projects
for DTC genetic testing (e.g., openSNP [10]). They
thus started a crowdsourcing project [11] to attract the
attention of potential collaborators who might be able
to analyse the data and return results that could com-
plement their existing knowledge about their personal
genomes. To emulate the principles of participatory medi-
cine, the current study was designed to follow these princi-
ples: 1) all experiments must be carried out with private
funds and as a private effort (i.e., using no public grant
money, donations); 2) all individuals involved need to
provide informed consent; 3) analyses are to be carried
out by combining results from personal investigation
and crowdsourcing efforts and 4) whenever possible,
advice is to be taken from professional genetic counsel-
lors and clinicians should any predicted risk require it.
Once consent was provided, saliva samples were extracted
using free sample Oragene kits and shipped to the Beijing
Genomics Institute (BGI) at Shenzhen, China, for sequen-
cing. With very limited financial resources and the simple
proposition of sharing personal genomics data widely on
the Internet, different sets of raw data and results were
posted through blogging and social networks, describing
the shared data, and reporting how results affected the
family [12].
All the personal genome data were made available via
figShare [1] with a public domain license (CC0), which
means that companies and scientists can use the data
without having to acknowledge or return any results to
the family. This decision to put the personal genomics
data in the public domain sped the process of adoption
and collection of data by third parties, motivating several
companies and scientists to contribute to the analysis.
The companies included Oxford Gene Technology,
InSilico Genomics, Diploid Genomics, BIOBASE, Orion
Integrated Biosciences, and GeneTalk. Qiagen Ingenuity
variant analysis was performed by a contributing scien-
tist. Scientists or students who joined the crowdsourcing
project at different stages added the remaining contri-
butions. The combined crowdsourcing analyses have
allowed the family to compile results from many dif-
ferent genome and metagenome tools.
The exomes have been used in a variety of tutorials,
some of them in the USA, e.g., National Institute of Al-
lergy and Infectious Disease, and some others in Europe,
such as the Clinical Genomics module at the University
of Navarra’s, MSc course in Biomedical Research taught
by M.C. or an exome analysis module developed by
P.N.R. for the bioinformatics curriculum at the Free
University of Berlin. Some of the results from research
assignment in taught courses have been fed back to the
family, constituting new research additions (e.g., section
on hair colour by N.T.).
In this article we present the experiences, results
and a discussion of this whole process, which has
been ongoing since 2009. In a previous publication
[5] we presented findings and results derived from
the analysis of the 23andMe genotypes from five
members of the Corpas family using only SNP chip
data as well as one exome and comparing extracted
SNPs with SNPedia annotations. We now extend the
study and analysis to the personal exomes of four
members of the family and a metagenome of one of
them (sadly the missing fifth exome was not to be
performed due to the demise of a family member).
We call members of this family Mother, Father, Aunt,
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Daughter and Son (Fig. 1). We contextualise the ex-
ome sequence analysis for the quartet comparing
23andMe SNP chip data with exome-derived varia-
tions, extending SNP chip data analyses with new
methodologies to provide the most complete pos-
sible overview of genotype-phenotype associations
making use of all crowdsourced results to date. In
addition, we also delve into the ethical hurdles and
barriers encountered by the family and the lead sci-
entist of this work, who is also a member of the
family.
Results
Comparison of exome and 23andMe data
In order to assess the quality of the data, we first
compared the variant calls from the exomes to those
of the previously analysed 23andMe SNPs from the
same family members. SNPs were matched by ID
(not by coordinates) in both the VCF exome and the
23andMe files. The scripts and data used are available
via figShare. We found that exome variant calls and
23andMe SNP chips share 36,315 SNPs for Daughter,
39,624 for Father, 40,234 for Mother and 22,233 for
Son. Son was genotyped using the 23andMe SNP
chip version 2 and the remaining family members
with version 3, hence Son has substantially fewer var-
iants common to the exome and SNP results than
the other family members. Next, we analysed the
SNP calling quality for the exomes. We found that
most ‘non-concordant’ SNPs (23andMe SNPs not
present in the exome) have low coverage (under 10
fold). Figure 2 shows the distribution graphs for
coverage in the quartet.
Among the filtered non-concordant SNPs, opposite
strand SNPs and haploid predictions were included. For
most errors it was not possible to establish whether
the SNP calls by 23andMe or by exome analysis were
erroneous. In some cases, no clear Mendelian inherit-
ance error was found because both inferred genotypes
could result in the observed family tree. For instance,
rs11580218 in Father's exome genotype was GA and
in 23andMe it was GT. According to dbSNP [13],
rs11580218 has the alleles A/G/T.
Hair colour in the Corpas Family
The main reason for focusing on the hair colour genet-
ics of the family is because Son has three offspring, all
of them with red hair, despite his black hair colour.
Fig. 1 Family tree of the five individuals and the DTC tests carried out using crowdfunding and private funds. Females are represented as circles
and males as squares. The genealogic tree represents the relations among the family members
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Therefore, the objective of this section is to explain hair
colour in the Corpas family using different SNP variants
and comparing the genotypes of the family with other
European populations. SNP data for this analysis were
collected from the 23andMe SNP chips for 5 members
of the Corpas family (including aunt). Figure 3 shows
the distribution of red hair in Europe and the region
where the Corpas family is originally from (bottom
left orange arrow).
We characterised 27 SNPs from 10 genes associated with
hair colour from the Corpas family: SLC45A2 (rs16891982,
rs28777); IRF4 (rs12203592); TYRP1 (rs2733832, rs683);
TPCN2 (rs35264875, rs3829241); TYR (rs1042602, rs13
93350); SLC24A4 (rs4904868, rs2402130); OCA2 (rs18
00407, rs7495174); HERC2 (rs12913832, rs7183877, rs11
635884 rs916977, rs8039195); MC1R (rs1805005, rs18
05006, rs2228479, rs11547464, rs1110400, rs1805008, rs88
5479) and ASIP (rs1015362, rs2378249). Significant
differences (p <0.05) in the genotype distribution were
sought. Genotypes with significant differences between
the Corpas family and a reference population are shown
in Fig. 4.
Principal Component Analysis (PCA) was performed to
analyse the distribution of variants in members of the
Corpas family. This analysis showed a clear difference
between the family member with red hair (Aunt) and
those with dark brown hair (Fig. 5). This difference could
be explained due to variants in the MC1R gene [14, 15]. In
addition, Aunt was found to have a different genotype for
rs916977, rs8039195 and rs7183877 in the HER2 gene.
Both populations (Corpas family and reference) have
similar genotype pattern and significant differences are
only present in variants of 9 SNPs. According to previous
studies [16], genotype of hair colour SNP variants are
different between the two European populations. Never-
theless, few differences have been found between these
two cohorts, which may be due to the Polish population
of the reference study having red hair preferably [17] and
red hair being present in the Corpas family. In addition,
we have been able to successfully conclude that Son is
Fig. 2 Distribution of coverage for all non-concordant SNPs between exome calls and 23andMe chips
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indeed a red hair carrier, explaining why all his offspring
has red hair.
Analysis of exomes from four different platforms
The VCF file for the exome quartet was analysed
using a crowdsourced approach. Figure 6 displays
the summary of main findings for associations
between observed variants (evidence) and their pre-
dicted phenotype. Each of the methods uses differ-
ent pipelines offered by four different platforms,
including Genome Trax of BIOBASE (Qiagen, Beverly,
MA, USA), Ingenuity Variant Analysis (Qiagen, Redwood
City, CA, USA), Diploid genome interpretation service
(Diploid Genomics, Leuven, Belgium), and GeneTalk
(GeneTalk, Berlin, Germany). One of the main observa-
tions from this combined analysis is that each platform
provides a substantially different set of results.
Within the different analyses, there are common
trends for most members of the family. For example,
Genome Trax predicted that all members of the
family are susceptible to preeclampsia. It also pre-
dicted a deleterious mutation in the Fanconi An-
aemia FANCA gene in all quartet members except
Mother. The Ingenuity variant analysis, based on a
dominant genetic model, predicted pathogenic variants
in ectonucleotide pyrophosphatase/phosphodiesterase
1(ENPP1) and a likely pathogenic variant for the
melanocortin 1 receptor (MC1R) in the three family
members except Father, associated with red hair and
non-tanning skin.
Diploid reported two main findings for all family
members: a) they all carry a variant that has been associ-
ated with an increased resistance to the common HIV
strain infection and b) they all are predicted to have wet
type earwax. GeneTalk did not predict any trait that is
common to all members of the family. For Son, it pre-
dicted a greater risk of renal colic from kidney stones.
Our Additional files 1, 2, 3 and 4 document provides the
complete reports from analysis platforms. On the whole,
the results have not revealed any clear genetic risk
Fig. 3 Distribution of red hair among contemporary European populations. The arrow (bottom left) indicates the origin of the Corpas family.
[Image: James McInerney; public domain]
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factors that would necessitate substantial changes in
lifestyle or medical management.
Interpretation and relevance
An important question for DTC genomics analysis is
whether consumers will be able to interpret the
findings without genetic counselling or other medical
advice. One of the authors (P.N.R.) is active in the
field of medical genetics, and has attempted to assess
the understanding of the family before and after
discussions with Son about the findings. Son (Manuel
Corpas), who is himself a scientist and bioinformatician,
Fig. 4 Genotype frequency of SNPs with significant differences between the Corpas family (purple) and a Polish reference population (green).
See Methods for details on how the reference population was obtained. a rs122203592; b rs7183877; c rs2402130; d rs12913832; e rs11635884;
f rs916977; g rs1800407; h rs11547464; i rs1015362
Fig. 5 Score plots generated from the principal component analysis of Corpas family genotypes for hair colour. Red and grey shaded areas show
red and dark-brown hair respectively
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has no medical background but is still likely to be
much better able to interpret the relevance of the
findings than a member of the general public without
either medical, bioinformatics, or scientific training.
We have held several discussions about the reports of
the four DTC providers. Perhaps one of the most
striking observations about the reports is the sheer
number of findings predicted to be deleterious. A
typical exome displays tens of thousands of variants
compared with the genomic reference sequence, up to
roughly 10,000 of which are predicted to lead to
nonsynonymous amino acid substitutions, alterations
of conserved splice site residues, or small insertions
or deletions. Even after filtering out common variants,
hundreds of variants of suspected medical relevance
may remain. In fact, each genome is thought to
harbour about 100 genuine loss-of-function variants
with about 20 genes completely inactivated [18].
Son reported that the list of potentially relevant var-
iants conveyed by the DTC providers were simply too
copious to evaluate in detail in discussions within his
family. Genome Trax reported 162 variants in candi-
date genes as deleterious. These included homozygous
variants calls in genes related to cancer (BRCA1,
APC, MEN1), congenital malformation syndromes
(TCOF1), metabolic deficiencies (FBP1, HEXA), and
neurological diseases (FUS, MLC1, DMD). “Major
variants”, included the LYZ gene that was homozy-
gous in Son and heterozygous in each parent. Muta-
tions in this gene are associated with familial visceral
amyloidosis (OMIM: 105200), a disease characterized
by chronic nephropathy, arterial hypertension, and
hepatosplenomegaly. The report notes that the allele
is rare in the general population and is predicted
deleterious by a bioinformatics tool. The variant in
question is listed in dbSNP with ID rs1800973, which
is reported to have a minor allele frequency of 0.021.
Since familial visceral amyloidosis has an autosomal
dominant mode of inheritance, and none of the
family members show signs of this serious disease,
the variant can confidently be classified as non-
pathogenic.
Another variant flagged by the Genome Trax ana-
lysis involved the P2RX5 gene. It is noted that each
parent is heterozygous for a frameshift deletion, but
the Son is homozygous wild type. The variant was
Fig. 6 Comparison of most significant exome results from the crowdsourced analyses of the Corpas family quartet by four different platforms:
Genome Trax, Ingenuity Variant Analysis, Diploid and GeneTalk. The different predicted phenotypes and their evidence are represented as
present (red highlight) or absent (blank) for each of the family individuals. We find that there is no overlap among reported top results from the
four companies
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highlighted because it is associated with “allogenic
cytotoxic T lymphocyte response”. However, the
publication that reports this finding was referring to
an allogeneic cytotoxic T lymphocyte response in a
patient with chronic myeloid leukemia after donor
lymphocyte infusion. This patient was found to have
the frameshift mutation in homozygous state [19].
Since parents are heterozygous, and Son is homozy-
gous wild type at this position, and since no family
member has been diagnosed with chronic myeloid
leukemia, from a medical standpoint this finding is
irrelevant.
The variant c.2562T > G was reported to cause al-
tered splicing in CFTR, the cystic fibrosis gene.
Mother is reported heterozygous for the variant, and
Son is reported as being homozygous for the wild
type, with the interpretation that this is just a
disease-associated polymorphism. The variant was
initially reported to be associated with increased
CFTR exon skipping in healthy individuals and was
thought to disrupt an exonic splicing enhancer, al-
though no experimental proof was provided for this
assertion. The variant is listed in dbSNP under
rs1042077 with a minor allele frequency of 44 %,
and is interpreted as “Benign/Likely Benign” in Clin-
Var [20]. Medical interpretation would classify this
as irrelevant, again especially in light of cystic fibro-
sis being an autosomal recessive disease and the lack
of any convincing evidence of pathogenicity.
A predicted pathogenic variant in the gene STOX1
was found to be homozygous in Son. Some muta-
tions in this gene are associated with preeclampsia,
which is noted to be a condition only relevant in
pregnancy and thus not applicable to Son. While this
interpretation is reasonable, the fact that this variant
(rs1341667) has a population minor allele frequency
of 36.7 %, makes it unlikely that it is a large-effect
mutation that would be a major risk factor.
The Ingenuity Variant Analysis software predicted
a number of single nucleotide variants as pathogenic
(Fig. 6). For instance, NM_006208.2:c.2230 + 1G > A
in the ENPP1 gene has been associated with meta-
bolic syndrome in obese childhood [21, 22] and is
observed in Mother, Son and Daughter. A variant in
MC1R (NM_002386.3:c.425G > A, p.R142H) has also
been predicted to be likely pathogenic, was observed
in Mother, Son and Daughter, and has been reported
to be associated with increased risk of developing
melanoma [23]. In fact Aunt (analysed using
23andMe data) sadly passed away in 2013 as a con-
sequence of malignant melanoma [1]. Further, a vari-
ant in the SET binding factor 1 (SBF1) gene
(NM_002972.2:c.3157C > T, p.R1053W) is observed in
all samples except Father. SBF1 is associated with
demyelinating peripheral neuropathy and Charcot-
Marie-Tooth disease type 4B3 (OMIM: 615284).
Certain variants that occur in Father, Son and Daughter
(not Mother) are in the excision repair cross-
complementation group 4 (ERCC4) gene and the zinc
finger protein 335 (ZNF335). A mutation in the ERCC4
gene can be observed with prostate cancer [24] and
breast cancer [25].
The report from GeneTalk was prepared by the
coordinator of the project, Peter Krawitz, who is a
medical doctor. GeneTalk provides a consideration of
variants in a number of genes and rules out medical
relevance for almost all of them, but does discuss the
possibility that a de novo variant in SLC26A6, which
codes for an anion exchanger, might limit the rate of
intestinal oxalate reabsorption [26]. This is a risk
factor for oxalate kidney stones and renal colic, even
though mutations in this gene have not previously
been found to be causative of human disease. It should
also be noted that the evaluation of Peter Krawitz was part
of the crowdsourcing project described here, but that
users of GeneTalk by default do not receive a medical
evaluation of the variants.
The exome analysis by Diploid Genomics, yet
again, emphasised a different set of variants. The
heterozygous presence of a variant of the TPMT
gene (denoted as TPMT*9) was detected in both
Father and Daughter. Given this is an extremely rare
allele, its exact functional status and pharmacological
implications are still preliminary, but carrying this
allele has been suggested to have possible implica-
tions for thiopurine toxicity [27–29]. Father was
shown to carry one normal and one defective allele
of the CYP2C19 gene, denoted as CYP2C19*4. This
intermediate metaboliser status can impact the
efficacy of drugs metabolised by the CYP2C19 en-
zyme, such as clopidogrel.
Analysis of son’s metagenome
To date only one individual from the Corpas family has
undergone metagenome sequencing. Hence here we re-
port the crowdsourced analysis from this individual only.
Taxonomical composition analysis of more than 2 mil-
lion 100 nucleotide reads was performed using a library
of microbial genomic signatures and motif fingerprints
based on [30, 31]. Figure 7 shows the percentage of mi-
crobial species for whose DNA is present in the sample.
Approximately 39 % of the DNA belonged to genomic
signatures of the species Faecalibacterium prausnitzii,
excluding all known strains, 18 % to uncultured bacteria
and rest to ~1000 bacterial species belonging to the
Bacteroides and Firmicutes phyla. These include the
genera Megasphaera spp., Bacteroides spp., Coprococcus
spp., and Clostridiales spp. Less than 1 % of DNA was
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mapped to lytic bacteriophages, members of genera
I3likevirus, T4likevirus and Phikzlikevirus of the family
Myoviridae. No motif fingerprints corresponding to
known viruses infecting eukaryotic cells were detected.
Discussion
We have presented the results of the crowdsourcing of
the analysis of a genomic dataset for a family. The
current lack of whole-family personal genomics data
available for public use has been a significant factor in
the success of this family’s crowdsourcing enterprise,
attracting the attention of scientists and companies to
contribute results. We have contributions from scientists
who wanted to carry out an experiment to analyse a
cohort of individuals or test data for development of
new tools (SNPedia tools [7], Ingenuity analyses) or
for demonstrating new products to prospective cus-
tomers and clients (InSilicoDB, BIOBASE Genome Trax,
Orion Integrated Biosciences Inc., GeneTalk, and Diploid
Genome Interpretation).
The main goal of this family study has been to explore
the utility of DTC genomic analysis in a family setting
with a data derived from personal genotypes, exomes
and metagenomes. In order to achieve this objective,
many obstacles had to be dealt with (e.g., finding a
sequencing provider, shipping samples, establishing the
appropriate ethical framework to perform and publish
the analyses). We expect this study to pave the way for
other families who might wish to actively engage in
participatory medicine and share their experiences.
Some individuals have already made their genome
sequences public (e.g., Personal Genome Project) and
many more individuals have done so with their 23andMe
data (e.g., Genomes Unzipped). The Corpas family de-
cided to take the unprecedented move of publishing
their exome and microbiome data and analyses on the
Internet under a CC0 license waiver, the least restrictive
type of license. To our knowledge, this is the first
reported family to engage independently in genomic
citizen science by publishing their identities and per-
sonal genomes on the Internet. This does not mean that
the family encourages everybody to follow this example;
the family does request, however, other researchers and
the general public not to censure this decision. This has
allowed them to explore their personal genomes to
an extent it would have been impossible at this time
otherwise.
It has been argued that individuals have more control
due to participatory nature of research enabled by hav-
ing access to personal genomic data. However, it might
be also the case that by letting individuals share their
data and accept more responsibility about potential
consequences, they lose their control on their data and
results they might receive. In addition, posting data in
such an identified way would make personal genomic
data sharing an irreversible decision in nature, given the
fact that withdrawing yet shared data from the web is
not a feasible option.
In order to satisfy established ethical conventions by
the community, ethical research and advice were sought
Fig. 7 Metagenomics analysis of DNA in faeces of Son. The taxonomic composition based on DNA matching genomic signatures and motif
fingerprints of different bacterial and phage genomes is shown
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to create the appropriate framework in which to share
and report data and findings. Although the Internet and
private test providers rendered the personal genomic
data sharing a plausible practice, it is hard to perceive
that this is immediately translated to more power to
individuals. There are significant limitations on control-
lability of data which has to be taken into consideration
while promoting participant-centric approaches to re-
search. Participant centric research and in this case per-
sonal data sharing is often coupled with presuming a
higher level of responsibility and awareness for the par-
ticipants. Publicly sharing data will put third parties’ ac-
cess to data under no limit whatsoever. As a result, third
party researchers are not obliged to sign any contract or
abide by “terms and conditions” that normally set in
other research settings. This might raise concerns that
in case of any harmful uses by third party researchers,
there are no grounds for making researchers legally re-
sponsible. To this end, it is imperative to assure those
who engage in such initiatives are sufficiently informed
about implications and prepared to embrace the associ-
ated risks. It is not the objective of this research to ig-
nore current practice and established ethical procedures
in the data sharing of personal genomes (see NIH’s
elements of informed consent [32] and the Global Alli-
ance for Genomics and Health [33]).
A primary objective was to probe the extent to which
DTC genetic testing can provide meaningful results to
people who decide to purchase those tests privately. By
lowering the barriers for scientists and companies to ac-
cess these data, the family could increase the chances of
successfully crowdsourcing their analysis and receiving
results back. These data have been used for testing and
educational purposes.
The health care implications of the exome and meta-
genome data obtained in our study are at best uncertain.
It was remarkable that there was no overlap of the sets
of variants reported as significant by the four DTC
analysis providers. This is reminiscent of recent reports
on the low concordance of DTC analysis of SNP-based
testing, with substantial differences in the predicted
disease risks [34–36]. The lack of concordance between
the results of the DTC analyses of the Family’s exomes
illustrates the difficulties in using this kind of analysis
for participatory medicine at present, and it is not clear
if any of the findings have relevance for the clinical care
of the family at present. A further limitation of our study
is the fact that for economic reasons, whole exome
sequencing was performed at a relatively low average
coverage of about 30×. It has been noted that different
bioinformatic pipelines lead to different sets of called
variants [37]. We were limited to one pipeline pro-
vided online by InSilicoDB [9], and did not explore
the effects of different computational analysis strategies,
since this would not normally be available in a DTC
context.
We note that our results were not intended to com-
pare the ability of the DTC companies to identify
disease-causing mutations in the setting of human gen-
etics or oncology, which are the primary use cases for
exome sequencing. We provide the same starting point,
a VCF file, and the same starting end, the predicted phe-
notypes based on SNP variations from the VCF file. The
analyses that were conducted at a particular point in
time will have their own software versions and configu-
rations. It is thus almost impossible to have a 100 % re-
producibility of results due to the difficulty posed by the
various formats presented from the different providers
and the dynamics of the evolution of methods or the
businesses themselves.
The metagenomic analysis of Son’s fecal microbiome
did not identify any actionable findings. The most abun-
dant bacterium in the sample, Faecalibacterium prausnit-
zii, is thought to be protective [38], but there is currently
no accepted analysis strategy that would allow one to
make certain conclusions about the medical relevance of
the results.
Conclusion
In this study we have confined ourselves to the evidence
given by DTC companies and applied different software
for interpretation. One of our main aims was to simulate
what it will be for a family of the future to analyse their
personal genomes privately. At current costs, however,
this type of analysis could hardly be afforded by most
families globally as genetic testing and counselling would
have been too expensive. This may change in the future
as the cost of analysis drops.
We have shown the extent to which private efforts in
participatory medicine can enhance knowledge or a family
of committed members wishing to analyse their personal
genomes. We have also shown how current technologies
allow entire families to engage in participatory research
with the help of the Internet without having to consult a
clinician beforehand. While carefully pondering risks and
seeking appropriate ethical framework, the Corpas family
decided to publish all their genetic data on the Internet to
crowdsource their analysis. It is our belief that the risks of
unintended uses of this family’s genomic data have far
been outweighed by the amount of information received
from the contributors to the crowdsourcing of data ana-
lysis. The results of the analysis provided an explanation
for the “surprising” hair colour of Son’s children, and
indicated the possibility that Father may be an intermedi-
ate metaboliser of the antiplatelet medication clopidogrel
(if there were an indication for this medication, an alter-
nate medication such as prasugrel might be considered).
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Combining the results of four providers, we have
offered an initial survey into the amount of knowledge
that can be gathered by a family using solely DTC
means. Results from the DTC providers vary widely
between them and no consensus seems to come up in
terms of actionable knowledge derived from the analyses.
In spite of the limited amount of information gained, this
study offers an initial survey on what is possible for any
ordinary family to learn about their own personal exomes
with current sequencing technology.
Methods
Ethical framework
Since the family bought the sequencing tests themselves,
they were not required to follow an Institutional Review
Board (IRB). We have, however, consulted with ethical
and genetic counselling experts regarding the appropri-
ate way in which to carry out the public sharing of
personal genomic data, which led us to adopt the
consent forms developed by Genomes Unzipped [39].
Genomes Unzipped developed a participant information
form clarifying the goals of the personal genomics data
sharing partakers were involved in. We adapted this
participant form and had it signed for all members of
the family quartet, clarifying the goals of the personal gen-
omic data sharing, potential risks and discomforts derived
from the (ab)use of the data shared on the Internet. This
consent process was discussed and agreed upon by the
Corpas family. Issues discussed included that, subsequent
to publicly sharing the data in the public domain, data
could no longer be considered to belong exclusively to the
individual; therefore, it would be hard to prevent un-
intended usages in the future, if not impossible. Addition-
ally, it was also indicated that from the legal stand point of
view (depending on jurisdictions) the family could relin-
quish all rights over the data by publicly sharing them.
From the standpoint of genetic counselling, it was also
apparent from our expert consultant that it is difficult to
compare our study to a 'gold standard' regulatory practice
because there is not such a thing yet. Hence we are unable
to assess the significance of the results in relation to
current practice.
Crowdsourced data
From 2011 onwards, the Corpas family decided to em-
bark on the journey of analysing their personal genomes.
When the first exome was obtained (2012), Next Gener-
ation Sequencing (NGS) was becoming routine in re-
search labs but was rarely available for DTC personal
genomic tests. Son was in fact the first DTC personal
genome that was sequenced by the BGI. After this, some
negotiations followed, with BGI agreeing to perform Illu-
mina Whole Genome Sequencing (WGS) for $4,000 per
person (2012 prices). To raise funds, a crowdfunding
campaign was started to fund $20,000 for five genomes
[40]. The crowdfunding plea offered in return (for a
significant percentage of the money expected to be
raised) early access to the data and printouts of publica-
tions derived from the analysis of the data. To our
knowledge this was the first time crowdsourcing and
crowdfunding were employed for the analysis of the
genomes of a complete family. The crowdfunding cam-
paign succeeded in raising ~ $3,300, precluding whole
genome sequencing of the entire family; hence exome
sequencing for 3 members of the family was performed,
a much cheaper alternative. The crowdfunding initiative,
together with private efforts from the family, provided
sufficient funds to generate a variety of datasets (Fig. 1).
The crowdsourced data include both raw and proc-
essed data. Because these data were obtained as DTC
tests, sometimes the source or platform utilised for the
same test was slightly different between individuals
because a different version of the platform was used
(indicated in Table 1). We have attempted to minimise
the impact of platform versions by using the same pipe-
lines and methods for alignment and variant calling.
The crowdsourced data encompass genotypes, annota-
tions, alignments, whole exome sequencing and metage-
nomics sequencing. The fastq files, the quartet’s VCF file
and their corresponding metadata are available via
figShare. InSilicoDB [9] was used to create the BAM and
VCF files. From InSilicoDB it can be downloaded the
fastq files, BAM files and VCF files for each member of
the family quartet [41–44]. Although the genotype data
and derived processed sources have been published else-
where [5], the exome sequencing data, and the corre-
sponding derived (processed) files and metagenomics
data are presented for the first time here. All variations
are single nucleotide variants (SNVs) and no indels or
copy number variations were used for this analysis.
The years in which the data were obtained are denoted
in Table 1 to roughly show the timeline of family tests.
The five sample genotype data obtained from 23andMe
SNP chips are in bed format, mapped to the human ref-
erence genome, NCBI36. These datasets were obtained
in the summer of 2009 (Son; version 2 of 23andMe;
~0.5 M SNPs) and January 2011 (Mother, Father, Daugh-
ter, Aunt; 23andMe SNP chip version 3, ~1 M SNPs per
individual). Whole exome sequencing from Son, Mother,
Father, and Sister was performed with DNA extracted
from saliva using Illumina HiSeq 2000 with an average
coverage of the target region of ~30×. The Son’s exome
was the first family member to be sequenced (January
2012). Agilent SureSelect Target Enrichment technology
(human all exon V4) for single-end reads was used to
capture DNA material. The other three exomes (Mother,
Father, and Daughter) were sequenced in January 2013
using the Agilent SureSelect 44 Mb human All-Exon
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design and sequenced using Illumina HiSeq. All sequen-
cing was done by BGI. The metagenomics sequencing
was performed for Son in August 2013 from a fecal
sample using Illumina (HiSeq 2000) shotgun sequencing.
We crowdsourced only the resulting two cleaned fastq
PE metagenomics files. These contain an insert size of
170 bp and a total size of 1,201 Mb of clean data (after
removal of carrier reads, low complexity reads, low qual-
ity reads, adapter contamination and duplicate reads).
Crowdsourcing the analysis
All of the crowdsourced contributors are included as
authors or defined as providers. Please see the “Author
Contributions section” or Table 1 for more details. The
policy adopted by the family was of complete transpar-
ency and of sharing all available data on the Internet as
soon as it was possible. Releasing all data under a
Creative Commons License 0 waiver effectively allowed
any possible use by third parties to the extent permitted
by law. After an initial period in which all data were
made available through the Manuel Corpas’ Blog [12], it
soon became apparent that this venue would make it
increasingly difficult to provide a centralised place with
all available data sources. A solution was found through
figShare, a resource that allows upload of data from
experiments, giving them a digital object identifier,
which makes them citable. figShare is also useful for
tracking the number of downloads, views and shares via
Facebook and Twitter. All data available for the family can
be accessed via figShare under the project tag ‘Corpasome’.
To date, the Corpas Family Trio Exome dataset (Mother,
Father, Daughter) in figShare has received 1247 views and
2 shares.
Following the posting of the family genome data (SNP,
exome and microbiome), notifications and contributions
have been received from users who found them useful
for their tool development or experiments. It therefore
became apparent how valuable these data were for many
scientists or companies developing or testing their prod-
ucts. This unexpected engagement by the community
can be mostly explained by the scarcity of publicly avail-
able familial data with an unrestricted license like CC0
Table 1 Summary of the crowdsourced data with its metadata. The dataset includes a total of 27 files and 18,463 MB of data
Type Provider Source Platform Format Year
obtained
# files Individuals(s) Approx.
size (MB)
Genotype 23andMe Saliva SNP chip v2 bed.zip 2009 1 Son 5
Genotype 23andMe Saliva SNP chip v3 bed.zip 2011 1 Mother 8
Genotype 23andMe Saliva SNP chip v3 bed.zip 2011 1 Father 8
Genotype 23andMe Saliva SNP chip v3 bed.zip 2011 1 Daughter 8
Genotype 23andMe Saliva SNP chip v3 bed.zip 2011 1 Aunt 8
Annotation SNPedia SNP chip v2 Phenotypes txt 2012 1 Son 0.3
Annotation SNPedia SNP chip v3 Phenotypes txt 2012 1 Mother 0.4
Annotation SNPedia SNP chip v3 Phenotypes txt 2012 1 Father 0.4
Annotation SNPedia SNP chip v3 Phenotypes txt 2012 1 Daughter 0.4
Annotation SNPedia SNP chip v3 Phenotypes txt 2012 1 Aunt 0.4
Whole Exome Sequencing BGI Saliva SE Illumina
HiSeq 2000
fastq.gz 2011 4 Son 2400
Whole Exome Sequencing BGI Saliva PE Illumina
HiSeq 2000
fastq.gz 2013 2 Mother 2000
Whole Exome Sequencing BGI Saliva PE Illumina
HiSeq 2000
fastq.gz 2013 2 Father 2000
Whole Exome Sequencing BGI Saliva PE Illumina
HiSeq 2000
fastq.gz 2013 2 Sister 2400
Alignment InSilicoDB SE Illumina HiSeq 2000 BWA bam 2013 1 Son 2900
Alignment InSilicoDB PE Illumina HiSeq 2000 BWA bam 2013 1 Mother 1800
Alignment InSilicoDB PE Illumina HiSeq 2000 BWA bam 2013 1 Father 1600
Alignment InSilicoDB PE Illumina HiSeq 2000 BWA bam 2013 1 Daughter 2200
Annotation InSilicoDB Bam from Son, Mother,
Father, Daughter
GATK VCF 2013 1 Son, Mother,
Father, Daughter
124.6
Metagenomics BGI Fecal frozen sample PE Illumina
HiSeq 2000
fastq.gz 2013 2 Son 1000
Total 27 18463.5
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on the Internet. Arguably this has worked to the advan-
tage of the family’s goal to crowdsource the analysis of
the Corpasome. Since the data were posted, results have
been received through a variety of channels including
comments to blog posts, direct emails, Twitter or Face-
book messages. Previous findings with the family using
mainly 23andMe data have been published elsewhere
[5]; results involving the analysis of NGS data integrating
four exomes and a microbiome and how they compare
to 23andMe data are reported here for the first time.
Red hair analysis
Reference data were obtained from two different sources.
First, Polish population data were obtained from a study
of Branicki et al. [17] who genotyped 385 samples of unre-
lated Europeans living in Poland and genotyped a subset
of 25 SNPs via mass spectrometry using Sequenom multi-
plexing. The second reference population refers to Nurses’
Health Study cohort from Han et al. [14] research, includ-
ing women with European ancestry, who were genotyped
using the Illumina Human-Hap550 array. Genotypes from
these two reference populations were deduced applying
Hardy-Weinberg equilibrium rules using the known
Minor Allele Frequency. Allele and genotype frequencies
were computed assuming that both populations are in
Hardy-Weinberg equilibrium. All the statistical analyses
were performed using SPSS Statistics (IBM, New York,
USA), Version 21 for Windows. In order to compare two
populations and discriminate if they have different hair
colour information, a goodness of fit test was conducted.
The goodness of fit test reported a contingency table that
could be used to study genotypic frequency differences
between “family” and “reference” cohorts. The χ2 and
Fisher´s exact statistic were calculated. In order to infer
statistical significance, only the Fisher exact test was used
due to the small size of Corpas family.
Exome data analysis
Processing of exome data was performed using InSilicoDB
[9] a web-based storage hub. For this dataset we used the
InSilicoDB pipeline v0.8. For all exomes, InSilicoDB
produced bam files with BWA [45]. This comprised the
alignment of an average 27,181,028 paired end reads per
sample to reference genome GRCh37/hg19. We removed
duplicate reads using Picard MarkDuplicates (v 1.70) [46],
performed local realignment around indels, base quality
score recalibration and variant calling with the Genome
Analysis Toolkit (GATK v 2.1.13) ‘best practice variant de-
tection method’ pipeline [1, 47]. We are aware that variant
calling using GATK version 2.1–13 has had known bugs
causing loss of function false positives. Variant discovery
was performed by InSilicoDB using joint variant calling,
outputting one VCF file for all four processed exomes.
Variant calling is executed independently for each sample,
followed by joint genotyping. No filtering was performed
at this stage. Quality values computed along the pipelines
were passed to the output VCF file and used in the next
stage. The VCF file was used to perform the analysis using
four types of software by different company providers.
1) Genome Trax: Filtered non-HGMD common
variants (>1 % allele frequency in dbSNP) [48].
Annotations were added from HGMD [48], the
GWAS Catalogue [49] and ClinVar [22]. Allele
frequencies for EVS and the 1000 Genomes [50]
pilot for the CEU population were provided. Also,
included nonsynonymous SNP functional
predictions of dbNSFP and Orphanet Inheritance
[51]. Effects such as hom-from-het, de novo or
compound-het variants have also been filtered.
Variants not passing the quality filter were
discarded. Variants were then ranked according to
the rules of being a known disease causing mutation
and being observed in a homozygous manner, or
observed in a heterozygous manner but the variants
for the associated gene were reported to be
dominant. Also, considered as additional evidence
(though, not used for ranking): rare variant’s allele
in the background population (in cases where such
numbers are known), variant predicted to be
deleterious by several prediction tools and an exact
match of the variant for the nucleotide change
(Additional file 2).
2) GeneTalk: Various filter settings were implemented
for analysis using GeneTalk [52]. First, variants of
Father and Mother were analysed to look for
screening of pathogenic heterozygous risk alleles
that might cause severe recessive disorders discussed
in the scientific literature. The following filters were
applied: a) functional filter (missense, nonsense,
splicing and frameshift); b) frequency filter (minor
allele frequency <1 %); c) Inheritance filter
(heterozygous genotypes only); d) annotation filter
(rated by GeneTalk community at least suspicious
in more than 1 individual. Second, the exome
quartet was then analysed assuming Son was
affected by some trait. We filtered for possibly
pathogenic homozygous variants that might cause
recessive diseases. Third, de novo mutations in the
son were filtered, removing all dbSNP entries,
setting the Son’s status to affected and filtering
for dominant.
3) Diploid genomics: Variants were filtered based on
quality, frequency, genomic position, protein effect,
pathogenicity and previous phenotypic associations.
For each selected SNP, location, genotype,
sequencing and allele depth, genotype quality, Phred
likelihood, SIFT [53] and PolyPhen-2 [54] scores
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were provided if available. The selected SNPs
were ranked according to their predicted deleterious
effect on the encoded protein. Homozygous calls
were also identified. SNPs for which a genotype-
phenotype
association is described in scientific literature, and
for which no conflicting results have been published,
were reported. In addition, the potential clinical
relevance of novel variants with a predicted
damaging effect (based on in silico prediction tools
and type of mutation) was also assessed. Risk factors
for common complex disorders were not part of the
analysis. All called SNPs that are not included in
dbSNP were selected from the VCF files (e.g., 22859
SNPs for Son). Of those, we filtered all SNPs that
are located in genes which are tested in the standard
Diploid analysis (about 3000 genes) (e.g., 1495 SNPs
for Son). Of this selection of SNPs, we further
selected those in the coding regions of the genes
(e.g., 88 SNPs for Son). For each of these SNPs, the
location, genotype, sequencing and allele depth,
genotype quality, Phred likelihood and SIFT and
PolyPhen scores are provided if available (see
Additional file 3). The selected SNPs are sorted from
high to low agony, based on the SIFT and PolyPhen
scores. None of the variants listed in the four
probands have proven clinical significance, we
can therefore not draw any conclusions for these
variants at this moment. However, we sorted the
variants by relevance based on the predicted
deleterious effect of the mutation on the encoded
protein (predicted by SIFT and PolyPhen scores
with scores of >0.8 and <0.05 predicted to cause
deleterious effects, respectively).
4) Ingenuity variant analysis: Analysis was performed
on four samples (Daughter, Son, Father and Mother)
by importing variant call data. All the variants were
annotated using the available content from the
Ingenuity Knowledge Base. The GRCh37 (hg19)
human reference genome was used as standard in
the application to compare with variants. A series of
filters discussed below were applied to the variants
(Additional file 1: Figure S1) At the top of the
variant filter cascade there were 300,717 called
variants across the four samples (2 cases, Daughter
and Son, and 2 controls, Father and Mother). These
variants were associated with a total of 17,838 genes
as defined by RefSeq gene model. A confidence filter
was applied to keep variants with call quality >20 for
the samples and, excluded variants in the top 5 %
most exonically variable 100 base windows in
healthy public genomes and the top 1 % most
exonically variable genes in 1000 genomes. The
common variants filter excluded variants with an
allele frequency of at least 3 % that were observed
in the populations in 1000 Genome project, public
Complete Genomics genomes and the Exome
Sequencing Project of the National Heart Lung and
Blood Institute. The predicted deleterious filter was
enabled to retain variants that were experimentally
observed to be associated with a phenotype
(pathogenic and likely pathogenic), associated with
gain of function (as established in the literature) or
associated with loss of gene function (frameshift,
in-frame indel, or start/stop codon change, and
missense, not predicted to be tolerated by SIFT
and PolyPhen-2). Genetic analysis filter was used
to construct different inheritance models. In the
‘Dominant’ inheritance model of the Genetic
Analysis filter (Additional file 1: Figure S1) the
variants were restricted to ‘transmitted’ (from controls
to cases), ‘heterozygous’ genotype in cases and, with
genotype occurrence in 2 of the 2 case samples at
variant level. In controls, other variants (homozygous,
compound heterozygous, haploinsufficient, hemizygous
and het-ambiguous) except ‘heterozygous’ genotype,
were excluded and, with genotype occurrence in at
least 1 of the 2 control samples at variant level. A
second Genetic Analysis filter was applied to exclude
‘homozygous’ and ‘heterozygous’ variants in controls
and, with genotype occurrence in 2 of the 2 control
samples at variant level.
Metagenomic (microbiome) data analysis
All metagenomic bioinformatics analyses were performed
on Orion Integrated Bioscience servers using motif
fingerprint generation (MF-gen) and CHAST algorithms
to identify protein segments conserved across a specific
taxonomy [30, 31]. MF-gen implementation is based
on the assumption that 12-amino acid long motifs do
not overlap linearly but they may be contiguous in 3-
dimensional space of non-redundant protein sequences.
CHAST assigned the taxonomy coverage of each motif
by exhaustive protein database released by GenBank.
From the scanning process three types of motif finger-
prints (MF) were recognised: 1) MF-Type I segments
specific to a given taxonomical group (e.g., species, sub-
types or strain); 2) MF-Type II segments shared by a
host and pathogen only. These might have been co-
opted by the pathogen to affect immune signalling,
regulatory or metabolic pathways. 3) MF-Type III, non-
specific segments shared by more than two species.
Each MF was mapped to their corresponding coding
region or genomic signature. For this analysis, the MF-
type I library for bacteria and viruses was scanned
through the individual’s reads and the taxonomic com-
position was represented as percentage.
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Deposition of data
Exome data used is deposited in figShare [http://figshare.
com/articles/Corpasome/693052] and can be freely down-
loaded and used under a CC0 license.
Supporting data
Supporting data and results are available in the Additional
files 1, 2, 3 and 4.
Endnote
1Contrary to the evidence, Aunt’s 23andMe report
predicts a decreased risk for Melanoma based on two
SNPs (rs1805007 and rs1805008) located in MC1R.
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